About Biotech Intelligence
What is Biotech Intelligence?
Biotech Intelligence is a free weekly briefing covering cross-border biotech licensing activity, CDE regulatory filings, corporate ownership structures, and BIOSECURE compliance developments. It is published for business development professionals, healthcare investors, and legal teams working on transactions between Asian and Western markets.
Each issue covers the week's most significant licensing deals, translates CDE filings from their original Mandarin, maps corporate ownership structures, and tracks BIOSECURE enforcement timelines. The goal is to give deal teams on both sides a clear, shared picture of what's happening.
Why This Exists
Cross-border biotech licensing between Asian and Western companies reached $137.7 billion in 2025, representing 38% of Big Pharma's $50M+ transactions in H1. As deal volume grows, so does the need for structured, primary-source intelligence on deal terms, regulatory status, and corporate structures across both markets.
The relevant data, CDE filings, corporate registry records, ownership chains, VIE structures, is spread across regulatory systems and languages. Biotech Intelligence brings it together in one weekly format, readable by anyone working on cross-border deals.
Written by Antony Tan
Antony holds an MS in Computational Biology from Harvard T.H. Chan School of Public Health and conducted research at the Broad Institute of MIT & Harvard, with a publication at NeurIPS 2025. BS Computer Science from the University of Toronto.
Fluent in English, Mandarin, and Cantonese, Antony works directly from CDE filings, NMPA regulatory documents, and corporate registries (Tianyancha, GSXT) in their original language, so both sides of a deal work from the same source material.
Our Methodology
Every briefing follows a rigorous process:
1. SOURCE
We monitor CDE filings, NMPA announcements, Chinese corporate registries (Tianyancha, GSXT), and deal announcements in both English and Chinese media.
2. TRANSLATE
CDE filings and regulatory documents are read by a native Mandarin speaker with computational biology training, not machine translation. Technical terminology is checked against pharmacological and regulatory standards.
3. ANALYZE
Deal terms are benchmarked against comparable transactions. Corporate structures are mapped through holding company registries. BIOSECURE exposure is assessed against BCC designation criteria.
4. DELIVER
Analysis is structured for business development and compliance professionals. Each issue concludes with key takeaways relevant to current deal and regulatory activity.
Independence & Ethics
Biotech Intelligence has no financial relationships with any company, institution, or government entity covered in this briefing. The author holds no stock positions in any company covered and does not accept consulting arrangements from companies under analysis. All analysis is independent. Where data is sourced from third-party reports or databases, the source is cited. Where deal values are estimated, methodology is noted.
This briefing covers analysis and research. It is not investment advice, legal counsel, or policy advocacy. Readers should work with qualified professionals for specific business, legal, or compliance decisions.
Contact
For questions, feedback, or consulting inquiries: antony@chinabiointel.com
Connect on LinkedIn · Google Scholar · GitHub